COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia

Anton Barchuk1*, Anna Bulina1, Mikhail Cherkashin2, Natalia Berezina2, Tatyana Rakova2, Darya Kuplevatskaya2, Oksana Stanevich1, Dmitriy Skougarevskiy1 and Artemiy Okhotin3

Abstract

Background: Studies of mRNA and vector-based vaccines used in different countries report acceptable levels of effectiveness against SARS-CoV-2 infection caused by the Delta variants of SARS-CoV-2. No studies estimated vaccine effectiveness (VE) of Gam-COVID-Vac and other vaccines used in Russia against symptomatic infection with Delta variant. In this population-based case-control study, we aimed to estimate the effectiveness of the Russian COVID-19 vaccines against symptomatic SARS-CoV-2 during the recent outbreak caused by the Delta VOC in October 2021 in St. Petersburg, Russia.

Methods: Cases were symptomatic patients with confirmed SARS-CoV-2 (using polymerase chain reaction (PCR) test) referred to low-dose computed tomography (LDCT) triage in two outpatient centres between October 6 and 14, 2021 during the Delta variant outbreak. We recruited the controls during the representative survey of the seroprevalence study conducted during the same period in St. Petersburg using random digit dialling. In the primary analysis, we used logistic regression models to estimate the adjusted (age, sex, and history of confirmed COVID-19) VE against symptomatic SARS-CoV-2 resulted in a referral to triage centre for three vaccines used in Russia: Gam-COVID-Vac, EpiVacCorona, and CoviVac.

Results: We included 1,254 cases and 2,747 controls recruited between the 6th and 14th of October in the final analysis. VE was 56% (95% CI: 48 to 63) for Gam-COVID-Vac (Sputnik V), 49% (95% CI: 29 to 63) for 1-dose Gam-COVID-Vac (Sputnik V) or Sputnik Light, -58% (95% CI: -225 to 23) for EpiVacCorona and 40% (95% CI: 3 to 63) for CoviVac. Without adjustment for the history of confirmed COVID-19 VE for all vaccines was lower, except for one-dose Gam-COVID-Vac (Sputnik Light). The adjusted VE was slightly lower in women — 51% (95% CI: 39 to 60) than men — 65% (95% CI: 5 to 73).

*Correspondence: abarchuk@eu.spb.ru

1 Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, 191187 St. Petersburg, Russia

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Mounting evidence suggests that vaccines remain effective against new variants of SARS-CoV-2, the virus that started the COVID-19 pandemic. Studies of mRNA and vector-based vaccines used in different countries report acceptable levels of effectiveness against SARS-CoV-2 infection caused by the new variants of concern (VOC) [1–7]. Waning immunity against new VOCs is another emerging concern as the follow-up time after the start of the vaccination programmes increases [8]. Therefore, timely and ongoing monitoring of the real-world effects for all vaccines used in programmes worldwide is crucial, given the geographical and temporal variation in global vaccine uptake and the spread of the new virus variants [9].

Only a few international studies assessed the vaccine effectiveness (VE) of Gam-COVID-Vac [10], a vaccine dominating the Russian COVID-19 vaccination programme. A study conducted in Hungary provided data on comparative VE in a national population-based programme that used several vaccines, including Gam-COVID-Vac from Russia and HB02 from China [11]. Gam-COVID-Vac effectiveness against SARS-CoV-2 infection and COVID-19-related mortality was comparable to mRNA vaccines and slightly superior to other vector-based vaccines. However, the Hungary study covers the period before the spread of the Delta VOC. The case-control study in St. Petersburg was the first available evidence of vaccine effectiveness (VE) against referral to hospital in patients with symptomatic SARS-CoV-2 infection in Russia during the spread of the Delta VOC [7]. However, that study had several limitations. The information on the vaccine type was not available, so the estimated VE represented an average effect of three vaccines used in St. Petersburg: Gam-COVID-Vac, EpiVacCorona [12], and CoviVac [13]. It was safe to assume that the St. Petersburg study approximated the effectiveness of Gam-COVID-Vac given that it accounted for 95% of city vaccinations during the period under study. However, the VE for the two other vaccines used in Russia — EpiVacCorona and CoviVac — remained unclear. More importantly, that study did not provide direct evidence on the VE against SARS-CoV-2 infection and symptomatic disease.

Another point of concern in observational studies of VE is the proportion of individuals with natural immunity which protects from re-infection [14, 15]. If case-control studies include individuals with immunity after infection as controls, that will likely underestimate the actual VE against SARS-CoV-2. To illustrate this point, more than 45% of the population have contracted the SARS-CoV-2 by the end of April, 2021 in St. Petersburg, Russia [16]. Preliminary study results show that seroprevalence in unvaccinated may be more than 75% in October, 2021 [17].

In this population-based case-control study, we aimed to estimate the effectiveness of the Russian COVID-19 vaccines against symptomatic SARS-CoV-2 during the recent outbreak caused by the Delta VOC in October 2021 in St. Petersburg, Russia.

Methods
Population and study design
This report summarised the results of the population-based case-control study of VE against the symptomatic disease with density sampling of controls conducted in October 2021 in St. Petersburg, Russia. We acquired information on cases and controls from two ongoing independent studies in St. Petersburg [7, 16] with population-based controls sampled at similar points in time when cases have occurred. Large cohort studies based on vaccine registries are probably the best tool to assess VE. Still, they require high-quality structured information about vaccination status and sufficient follow-up to collect a required number of outcomes. Without this type of information, population-based, case-control studies are a convenient tool that could help with the preliminary assessment of VE.

Our cases were symptomatic patients with confirmed SARS-CoV-2 (using polymerase chain reaction (PCR) test) referred to low-dose computed tomography (LDCT) triage. Our previous report describes in detail the source and information we collected for the cases [7]. In brief, we collected individual-level data from two outpatient triage centres of the Medical Institute named after Berezin Sergey (MIBS), a private medical facility contracted by the city government to provide triage service for nearly half of the city districts. Triage centres continuously collected this information from August 2021. In addition to the data collected for our previous case-control study, we added information on the vaccine type (Gam-COVID-Vac (Sputnik V and Sputnik Light), EpiVacCorona, and

Conclusions: Our preliminary results show that in contrast to other Russian vaccines, Gam-COVID-Vac is effective against symptomatic SARS-CoV-2 infection caused by Delta VOC. Effectiveness is likely higher than the estimated 56% due to bias arising from high prevalence of the past COVID-19 in St. Petersburg.

Keywords: Vaccine effectiveness, Case-control study, SARS-CoV-2, COVID-19
CoviVac) and the history of confirmed COVID-19, which we defined as the positive PCR test at least two months before the current episode.

We recruited controls from a survey of the seroprevalence study conducted in the same period in St. Petersburg. Our previous reports described the serosurvey design in detail [16, 18]. It includes a two-step approach: a survey conducted using random digit dial (RDD) and computer-assisted telephone interview (CATI) followed by an invitation to a serological test. The survey samples were representative of the population of the city in terms of sociodemographic characteristics. In addition, CATI included questions related to history of confirmed COVID-19 and vaccination status in line with information collected from cases.

For this study, we extracted information on all SARS-CoV-2 patients referred to the triage centre between the 6th and 14th of October, 2021 (which was the period when controls data from the survey were available).

Vaccination status, outcomes, and other variables
Vaccination status in our study was self-reported. Both cases and controls were asked about their vaccination status, vaccine type, the number of doses, and dates for the doses. If the exact day was not reported, at least the month and the year of vaccination were collected. Three vaccines were available in St. Petersburg during the pandemic: Gam-COVID-Vac two-dose (Sputnik V) and one-dose regimen (Sputnik Light), EpiVacCorona and CoviVac (both two-dose regimens). All vaccines were approved for primary vaccination, but Sputnik Light was specifically recommended as preferred option for the booster after COVID-19 infection. We assigned the full vaccination status to all participants (both cases and controls) who reported the second dose in September 2021 and earlier. We set full vaccination status for participants with uncertain vaccination dates, but this assumption was further addressed in the sensitivity analysis. We assigned partial vaccination status to participants who received only one dose but did not satisfy the criteria for full vaccination status. We have also analysed Sputnik Light vaccines as a distinct group. Participants who received one dose of Gam-COVID-Vac, but had not received the second dose till October entered the Sputnik Light group.

The primary outcome was the referral to LDCT triage with symptomatic infection and the positive PCR for SARS-CoV-2. Cases were patients referred to LDCT triage who underwent brief physical examination and computed tomography (CT). We were collecting CT-score (five gradations from 0 to 4), which represents lung segment involvement used in our previous study [7]. The secondary outcome was any lung injury as reported by LDCT in the triage centre (CT-score 1, 2, 3, or 4). We did not collect or use the hospital referral as an outcome in contrast to our previous study because official criteria for hospitalisation changed in the autumn of 2021 in St. Petersburg. Other variables include age, sex, history of confirmed COVID-19.

Analysis
We modelled our study plan following the WHO interim guidance to evaluate COVID-19 vaccine effectiveness [19]. We used unconditional logistic regression for our primary and secondary outcomes to estimate odds ratios (ORs) for vaccination status among cases and controls, which approximates ORs for the outcomes among the vaccinated and non-vaccinated patients. In the presence of a density control sampling scheme, it approximates the rate ratio from the respective cohort study [20]. This study design was previously used to assess risk factors for respiratory infections [21]. The VE was calculated as 100%×(1−OR) adjusted for age and sex. We corrected VE for the history of confirmed COVID-19 infection by performing the analyses in the dataset restricted to participants without the history of confirmed COVID-19.

In the sensitivity analysis, we explored the possible extent of misclassification. To address the misclassification for the vaccination dates for some participants, we have changed the status of controls with uncertain dates of vaccination to non-vaccinated. In addition, in another sensitivity analysis, we assumed that cases with missing vaccine names received Gam-COVID-Vac. We reported all results of sensitivity analysis in Supplementary Material.

Results
Overall, 1,254 cases and 2,747 controls were included in the final analysis. Study participants characteristics are presented in Table 1. Before October 2021, among cases, 288 (23.0%) received Gam-COVID-Vac (Sputnik V), 57 (4.5%) — one dose Sputnik Light, 19 (1.5%) — EpiVacCorona, and 37 (3.0%) — CoviVac. Similar proportions among controls were 937 (34.1%), 214 (7.8%), 15 (0.5%), and 88 (3.2%), respectively. Cases were on average older (27.9% were older than 60 years compared to 19.1% among controls) and the proportion of women was also higher among cases (63.1% among cases vs 53.7% among controls). Only 2 (0.2%) patients who were referred for LDCT triage had documented past COVID-19 confirmed by PCR test. The proportion of controls who reported positive PCR test in the past was 22.1%. Both cases and controls were relatively uniformly distributed across recruitment dates (October 6–14, 2021).

In the primary analysis without accounting for the history of confirmed COVID-19, the VE against
symptomatic PCR-confirmed SARS-CoV-2 infection adjusted for age and sex was 49% (95% CI: 40–56) for Gam-COVID-Vac (Sputnik V), 51% (95% CI: 32–64) for 1-dose Gam-COVID-Vac (Sputnik V) or Sputnik Light, -84% (95% CI: -267–84) for EpiVacCorona, and 35% (95% CI: 3–63) for CoviVac. In the analysis restricted to participants without a history of confirmed COVID-19, all point estimates of VE moved upwards, except for the Sputnik Light group. The VE was 56% (95% CI: 48–63) for Gam-COVID-Vac (Sputnik V), 49% (95% CI: 29–63) for 1-dose Gam-COVID-Vac (Sputnik V) or Sputnik Light, -58% (95% CI: -225–23) for EpiVacCorona, and 40% (95% CI: 3–63) for CoviVac (Table 2).

Crude and adjusted VE against any lung injury following the LDCT assessment is presented in Table 3. In the analysis restricted to participants without a history of confirmed COVID-19, all point estimates of VE against lung injury also moved upwards.

The adjusted VE against symptomatic SARS-CoV-2 infection was slightly lower in women (51%, 95% CI: 39–60) than men (65%, 95% CI: 53–73). It was also higher in younger age (Table 4). However, in the analysis restricted to participants without a history of confirmed COVID-19, all point estimates of VE against lung injury also moved upwards.

Table 1: Characteristics of cases and controls

|                      | Cases (%) | Controls (%) |
|----------------------|-----------|--------------|
| Age (mean (SD))      | 49.82 (16.14) | 45.68 (15.06) |
| Age (categories (%)) |           |              |
| 18-30                | 144 (11.5) | 419 (15.3)   |
| 31-40                | 275 (21.9) | 808 (29.4)   |
| 41-50                | 240 (19.1) | 499 (18.2)   |
| 51-60                | 245 (19.5) | 496 (18.1)   |
| 60+                  | 350 (27.9) | 525 (19.1)   |
| Sex (%)              |           |              |
| Female               | 791 (63.1) | 1,475 (53.7) |
| Male                 | 463 (36.9) | 1,272 (46.3) |
| Vaccine name (%)     |           |              |
| Gam-COVID-Vac (Sputnik V) | 288 (23.0) | 937 (34.1)   |
| Gam-COVID-Vac (Sputnik Light) | 57 (4.5) | 214 (7.8)    |
| EpiVacCorona         | 19 (1.5) | 15 (0.5)     |
| CoviVac              | 37 (3.0) | 88 (3.2)     |
| Other                | 23 (1.8) | 29 (1.1)     |
| No vaccine           | 830 (66.2) | 1,464 (53.3) |
| Vaccination status   |           |              |
| Non-vaccinated       | 830 (66.2) | 1,488 (54.2) |
| Partial vaccination  | 20 (1.6) | 46 (1.7)     |
| Complete vaccination | 404 (32.2) | 1,213 (44.2) |
| Reinfection          |           |              |
| History of confirmed COVID-19 | 2 (0.2) | 606 (22.1)   |
| No history of confirmed COVID-19 | 1,252 (99.8) | 2,141 (77.9) |
| Recruitment dates    |           |              |
| October 6            | 177 (14.1) | 329 (12.0)   |
| October 7            | 126 (10.0) | 246 (9.0)    |
| October 8            | 133 (10.6) | 306 (11.1)   |
| October 9            | 134 (10.7) | 275 (10.0)   |
| October 10           | 111 (8.9) | 227 (8.3)    |
| October 11           | 145 (11.6) | 392 (14.3)   |
| October 12           | 134 (10.7) | 487 (17.7)   |
| October 13           | 169 (13.5) | 234 (8.5)    |
| October 14           | 125 (10.0) | 251 (9.1)    |
COVID-19, the differences in VE by age group were smaller. In the sensitivity analysis, misclassification related to vaccine name and vaccination dates did not dramatically change VE estimates.

**Discussion**

This is the first study examining the comparative effectiveness of three COVID-19 vaccines used in Russia. Our study results assure that Gam-COVID-Vac is highly effective against symptomatic SARS-CoV-2 and severe COVID-19 pneumonia during the Delta VOC spread. We have shown that Gam-COVID-Vac provides at least 56% protection against symptomatic infection caused by the Delta VOC. However, the effectiveness is likely to be higher as it is difficult to account for all past SARS-CoV-2 infections in the Russian population. Furthermore, past COVID-19 is associated with decreased vaccine uptake in Russia. Our study’s apparent strength is the attempt to account for past infections in both cases and controls and show the resulting direction of possible bias. Assuming natural immunity is protective against re-infection, failure to account for it in populations with high seroprevalence would bias VE estimates downwards. Another possible representation of this is the change in Gam-COVID-Vac VE by age group after accounting for the history of confirmed COVID-19.

We have shown that the bias related to a significant number of unvaccinated individuals with a history of COVID-19 will likely lead to underestimating the effectiveness of vaccination from observational data. However, we remain uncertain about the possible magnitude of this bias. The individual-level data on past asymptomatic infection is challenging to obtain, if possible at all. Preliminary results show that seroprevalence in unvaccinated may be more than 75% in October, 2021 [17].

**Tables**

| Table 2 | Effectiveness of Vaccination against Symptomatic PCR-confirmed SARS-CoV-2 |
|---------|--------------------------------------------------------------------------------|
| Crude VE (95% CI) | VE adjusted for age and sex (95% CI) | VE adjusted for age, sex, and history of confirmed COVID-19 (95% CI) |
| Gam-COVID-Vac (2-dose Sputnik V) | 43% (34–52) | 49% (40–56) | 56% (48–63) |
| Gam-COVID-Vac (1-dose Sputnik Light) | 49% (31–63) | 51% (32–64) | 49% (29–63) |
| EpiVacCorona | -105% (-322–1) | -84% (-267–8) | -58% (-225–23) |
| Covivac | 34% (-3–49) | 35% (-3–59) | 40% (3–63) |
| Other | -22% (-127–34) | -26% (-125–29) | -1% (82–44) |
| Any vaccine: partial vaccination | 22% (-33–54) | 24% (-33–56) | 25% (-33–58) |

| Table 3 | Effectiveness of Vaccination against any lung injury |
|---------|---------------------------------------------------|
| Crude VE (95% CI) | VE adjusted for age and sex (95% CI) | VE adjusted for age, sex, and history of confirmed COVID-19 (95% CI) |
| Gam-COVID-Vac (2-dose Sputnik V) | 57% (48–64) | 64% (56–70) | 69% (62–74) |
| Gam-COVID-Vac (1-dose Sputnik Light) | 56% (36–70) | 58% (38–71) | 58% (37–72) |
| EpiVacCorona | -82% (-280–13) | -52% (-205–24) | -30% (-165–37) |
| Covivac | 43% (4–66) | 44% (5–67) | 49% (11–70) |
| Other | -22% (-137–37) | -24% (-130–33) | -1% (-89–46) |
| Any vaccine: partial vaccination | 33% (-24–66) | 35% (-30–64) | 36% (-25–67) |

| Table 4 | Effectiveness of vaccination against Symptomatic PCR-confirmed SARS-CoV-2 by age and sex |
|---------|------------------------------------------------------------------------------------------|
| Crude VE (95% CI) | VE adjusted for confirmed COVID-19 history (95% CI) |
| Age groups | |
| 18–30 | 70% (47–83) | 73% (51–85) |
| 31–40 | 54% (34–68) | 57% (38–71) |
| 41–50 | 53% (32–69) | 58% (38–72) |
| 51–60 | 39% (14–56) | 51% (30–65) |
| 60+ | 41% (21–56) | 52% (35–65) |
| Sex | |
| Male | 59% (47–68) | 65% (53–73) |
| Female | 42% (29–52) | 51% (39–60) |
St. Petersburg. In countries with higher vaccine uptake and lower seroprevalence VE estimated in observational studies is higher [5], but these estimates are not directly comparable with our results. The Omicron VOC spread will likely make the interpretation of the VE studies even more difficult. Direct comparison similar to the Hungarian study will be needed for the new variants [11].

Our study included information on three vaccines built using different platforms; however, it was not powered to provide any intergroup comparisons. E.g. while the difference between VE point estimates of CoviVac (40%) and Gam-COVID-Vac (56%) may reflect the superior effectiveness of Gam-COVID-Vac, it could have resulted from the random error.

Both vaccines, EpiVacCorona and CoviVac, were relatively rare in the population of St. Petersburg, and our study was underpowered for them. Therefore, our study provided only preliminary findings, given the relatively small sample size, especially for these two vaccines. More studies are needed to assess the VE of EpiVacCorona and CoviVac against new variants of SARS-CoV-2 for them to be used in the ongoing vaccination programme. Unfortunately, efficacy data is currently available only for Gam-COVID-Vac [22]. Booster campaigns now gaining more scientific support should only utilise vaccines with proven efficacy and effectiveness [23–25].

It is also worth mentioning that while the VE for CoviVac was beyond the VE for Gam-COVID-Vac, the estimate for EpiVacCorona VE was negative. The efficacy is not likely to be negative, so our results have two realistic explanations. First, individuals could change their behaviour after vaccination, but more likely negative VE is a marker for the bias arising from the undercounting of past COVID-19 in controls.

This is our second VE study in St. Petersburg, Russia, and it provides a promising independent and timely framework for assessing COVID-19 vaccines in Russia. Population-based case-control studies represent a critical post-registration tool to monitor VE against emerging SARS-CoV-2 VOCs. The Omicron VOC pandemic has not involved Russia by the end of 2021, but there are few doubts that it will affect the course of the pandemic in Russia as previously the Delta VOC had [16]. The lack of real-world evidence may be one of the reasons behind the modest uptake of vaccination in Russia. The majority in Russia does not deny the idea of vaccination but is hesitant [26].

Despite the wide use of case-control studies to assess VE, researchers should be aware of all possible biases arising from this study design. Unfortunately, the golden standard to estimate VE — randomised trials — are not applicable in the rapidly changing epidemiological situation, and we have to rely on observational study design. The varying VE against different SARS-CoV-2 variants is an example of a lack of generalizability for the results of randomised trials. Our study underlines the biases related to the population under study, but additional biases arise from the misclassification of exposure, e.g., vaccination status [27].

The self-reported vaccination status is an important limitation of our study. Several survey participants included in the control group have not reported the exact date of vaccination. While the overall number of such individuals was low, we assumed that the vaccination date for such individuals is likely to be several months from the interview date. However, we assigned them a “non-vaccinated” status in our sensitivity analysis, and the estimates were only slightly affected. Our definition for full vaccination status was also very conservative, as we decided to accept a minimum of six days between the second vaccine dose and study inclusion. While our decision was driven by the idea that we should not exclude participants without an exact date of vaccination, we do not think that this assumption would significantly bias the results. However, most of the studies choose 14-day period [5], and that should be taken into account when comparing our results to other studies.

We have undertaken additional attempts to identify cases (patients with symptomatic SARS-CoV-2 in October, 2021) who had the history of confirmed COVID-19 more than two months before the current episode. We were able to identify only two cases of re-infection. While underreporting may occur, it is also likely that a patient with re-infection that requires additional diagnostic follow-up is an infrequent event. Absolute risks of re-infection, especially of severe disease, are low for the Alpha, Beta, and Delta VOCs [28, 29]. However, more studies are needed to observe the risk of re-infection with new Omicron VOCs, as it is likely to be higher [30]. Overall, the risks may still be lower in absolute terms than for primary infection.

In our study, the VE in the Sputnik Light group was similar to two-dose Gam-COVID-Vac. However, the correction for the history of confirmed COVID-19 did not move the Sputnik Light VE upwards. Single Gam-COVID-Vac vaccination labelled as Sputnik Light was used as a booster after the COVID-19, so it is likely that the prevalence of past COVID-19 is higher in this group. The VE for Sputnik Light could represent the combination of single-dose boosted natural immunity mixed with single-dose vaccine.

Some of these limitations are inherent to observational study design. Still, other difficulties can be overcome by establishing a pre-existing framework for
real-time assessment of vaccine effectiveness as a part of epidemiological surveillance. We did not attempt to assess the duration of protection. Additional studies are needed to explore the waning effectiveness of Gam-COVID-Vac and other vaccines. Our sample size, risk of misclassification related to self-reported vaccination status, and possible selection did not allow its valid estimation. The cohort study with a large sample size and registered vaccination status is probably the best tool to assess waning effectiveness [31].

In conclusion, our preliminary results show that Gam-COVID-Vac effectiveness against symptomatic SARS-CoV-2 infection caused by Delta VOC is at least 56%, but is likely to be higher. However, estimating effectiveness is difficult due to the high prevalence of natural immunity in the population. Nevertheless, Gam-COVID-Vac significantly outperforms two other Russian vaccines whose effectiveness against symptomatic SARS-CoV-2 infection caused by Delta VOC is yet to be shown.

 Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12889-022-14202-9.

 Additional file 1: Supplementary material with the results of sensitivity analysis.

Acknowledgments
We acknowledge personal support from Vitaly Nesis (Chief Executive Officer, Polymetal International, plc). We are grateful to Alla Samoletova and Alexandra Vasilieva (European University at St. Petersburg) for science communication and administrative support. We thank the interviewers, nurses, and other personnel of the MIBS. We appreciate Yulia Stepanstsova (Chursina) input in coordinating phone-based interviews, Daria Danilenko, Aleksei Kouprianov and Daniel Munblit for insightful discussions. We also thank all study participants.

Authors’ Contributions
Anton Barchuk, Artemy Okhotin, and Mikhail Cherkashin conceived the study. Anton Barchuk, Artemy Okhotin, Mikhail Cherkashin, and Oksana Stanievich coordinated the study. Anton Barchuk, Artemy Okhotin, Dmitriy Skougarevskiy, and Anna Bulina drafted the first version of the manuscript. Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, and Oksana Stanievich contributed to drafting sections of the manuscript. Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya collected data for analyses. Anna Bulina and Anton Barchuk did data analyses. All authors participated in the study design, helped draft the manuscript, contributed to the interpretation of data, and read and approved the final manuscript.

Funding
Polymetal International plc funded the serological study. The main funder had no role in study design, data collection, data analysis, data interpretation, report writing, or decision to submit the publication. The European University at St. Petersburg and MIBS had access to the study data. The European University at St. Petersburg had the final responsibility to submit for publication.

Availability of data and materials
All analyses were conducted in R, study data and code is available online https://github.com/euspor/spb_covid_study20. Accession number is not applicable.

Declarations

Ethics approval and consent to participate
The Ethics Committee of the MIIBS approved the VE study on June 21, 2021. The Ethics Committee of the Pavlov First Saint Petersburg State Medical University approved the joint study of COVID-19 VE in St. Petersburg on July 15, 2021. All research was performed following the relevant guidelines and regulations. All participants signed the informed consent upon referral to the LDCT triage. The joint study of COVID-19 vaccine effectiveness in St. Petersburg was registered at ClinicalTrials.gov (NCT04981405, date of registration: August 4, 2021). This publication covers the data collected at the two outpatient centres of the MIBS that contributed to the study data. The Research Planning Board of the European University at St. Petersburg and the Ethics Committee of the Clinic “Scandinavia” approved the seroprevalence study on May 20, 2020 and May 26, 2020, respectively. Consent was obtained from all participants of the study. The study was registered with the following identifiers: ClinicalTrials.gov (NCT04406038, submitted on May 26, 2020, date of registration: May 28, 2020) and ISRCTN registry (ISRCTN 11060415, submitted on May 26, 2020, date of registration: May 28, 2020). The data used in this study were anonymized before use.

Consent for publication
Not applicable.

Competing interests
Anton Barchuk reports personal fees from AstraZeneca, MSD, and Biocad outside the submitted work. Other authors have no conflict of interest or competing interests to declare.

Author details
1 Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, 19187 St. Petersburg, Russia. 2 Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, 194354 St. Petersburg, Russia. 3 Tarusa Hospital, Karla Libknikhita Ulitsa 16, 249100 Tarusa, Russia.

Received: 28 June 2022 Accepted: 14 September 2022
Published online: 22 September 2022

References
1. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa21119270.
2. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 Vaccine Effectiveness in New York State. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2116063.
3. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2.
4. Tarof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranaasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–16.
5. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585–94.
6. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. Emerg Microbes Infect. 2021;10(1):1751–9. https://doi.org/10.1080/22221751.2021.1969391.
7. Barchuk A, Cherkashin M, Bulina A, Berezina N, Rakova T, Kuplevatskaya D, et al. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study. BMJ Med. 2022;20(1):312.
8. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwells KB, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2116597.
9. Wang W, Wu Q, Yang J, Dong K, Chen X, Bai X, et al. Global, regional, and national estimates of target population sizes for Covid-19 vaccination: descriptive study. BMJ. 2020;371. https://doi.org/10.1136/bmj.m4704. https://www.bmj.com/content/371/bmj.m4704.full.pdf.

10. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97.

11. Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, et al. Nationwide seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. Sci Rep. 2021;11(1):1–9.

12. Ryzhikov A, Ryzhikov E, Bogryantseva M, Usova S, Danilenko E, Nechaeva E, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I-II). Russ J Infect Immun. 2021;11(12):283–96.

13. Kozlovkaya L, Piniaeva AN, Ignatyev GM, Gordyechuk IV, Volok-VP, Rogova YV, et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. 2021;10(1):1790–806.

14. Gazit S, Shlezinger R, Perez G, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity. Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. Clin Infect Dis. 2022;75(1):e545–e551. https://doi.org/10.1093/cid/ciac262.

15. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(12):1–4.

16. Barchuk A, Skougarevskiy D, Kouprianov A, Shirokov D, Dudkina O, Tursun-zade R, et al. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data. PLoS One. 2022;17(6):e0266945.

17. Eusp org. U 83% peterburzhcev est antitela k koronavirusu. 2021. https://eusp.org/news/u-83-peterburzhcev-est-antitela-k-koronavirusu.

18. Barchuk A, Skougarevskiy D, Titaev K, Shirokov D, Raskina Y, Novkunkskaya A, et al. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. JID Rep. 2021;11(1):1–9.

19. WHO. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021. https://apps.who.intiris/handle/10665/340301.

20. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205–13.

21. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. Cigarette Smoking and Invasive Pneumococcal Disease. N Engl J Med. 1990;324(10):681–9. https://doi.org/10.1056/NEJM199003093241002.

22. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatullin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81.

23. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400. https://doi.org/10.1056/NEJMoa2114255.

24. Barda N, Dagan N, Cohen C, Hernán MA, Lipstich M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100.

25. Patalon T, Gazit S, Frimer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Intern Med. 2021. https://doi.org/10.1001/jamainternmed.2021.7382.

26. Larson HJ. The state of vaccine confidence. Lancet. 2018;392(10161):2244–6.

27. Rodrigues L, Smith P. Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. Epidemiol Rev. 1999;21(1):56–72.

28. Abu-Raddad LJ, Chemaitelly H, Bertolini R. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. N Engl J Med. 2021;385(26):2487–9. https://doi.org/10.1056/NEJMc2108120.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.